If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Nuformix, Open Orphan, Zoetic International and Live Company Group
Dr Dan Gooding, Chief Executive Officer of Nuformix (NFX) discusses how their placing will allow the Group to strengthen its overall position during negotiations and accelerate progress.
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Maurice Treacy, Chief Commercial Officer of Open Orphan (ORPH) reveals they have signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform.
Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services businesses. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform, enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.
(Interview starts at 10 minutes 4 seconds)
Nick Tulloch, CEO of Zoetic International (ZOE) provides an update on its operations and current trading including six new CBD products to be launched in the UK ahead of Christmas.
Zoetic is a vertically integrated CBD business with indoor and outdoor growing facilities in Western Colorado. The company sells a range of products in the US and UK through two brands. In addition the company has a portfolio of natural resources projects, the flagship of which is a 7.5% carried working interest in 8 producing wells east of Denver. The company announced on 4 September 2019 that it would seek to sell these assets as it focuses on its CBD business.
(Interview starts at 20 minutes 7 seconds)
David Ciclitira, Chairman, Live Company Group (LVCG) provides a further update on the deferred consideration on their purchase of Bright Bricks which they acquired in October 2018.
Live Company Group is a live events and entertainment Company, founded by David Ciclitira in December 2017. The Company was admitted to trading on AIM in December 2017, following the reverse acquisition of Brick Live Group and Parallel Live Group by LVCG.
(Interview starts at 28 minutes 52 seconds)